Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Abstract Background Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly...

Full description

Bibliographic Details
Main Authors: Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Jia-Yu Wang, Yang Luo, Qing Li, Ying Fan, Bing-He Xu
Format: Article
Language:English
Published: BMC 2016-04-01
Series:Chinese Journal of Cancer
Subjects:
Hormonal therapy
Maintenance capecitabine monotherapy
First-line capecitabine-based combination chemotherapy
Metastatic breast cancer
Online Access:http://link.springer.com/article/10.1186/s40880-016-0101-7

Internet

http://link.springer.com/article/10.1186/s40880-016-0101-7

Similar Items